EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 9-21

  Li, Li ^a   Dutra, Amalia ^c   Pak, Evgenia ^c   Ill, Joseph E Labrie ^b   Gerstein, Rachel M ^b   Pandolfi, Pier Paolo ^d   Recht, Larry D ^e   Ross, Alonzo H ^a,b  

^a Department of Biochemistry and Molecular Pharmacology ^*  (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploidy; EGFRvIII; Glioblastoma; Neural precursor cells; PTEN

Indexed keywords

CD133 ANTIGEN; CHECKPOINT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSFORMATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 15; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GLIOBLASTOMA; IONIZING RADIATION; MOUSE; NEURAL STEM CELL; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CENTROSOME; CHROMOSOMAL INSTABILITY; FEMALE; GLIOMA; HUMANS; INTEGRASES; INTERMEDIATE FILAMENT PROTEINS; KARYOTYPING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; NIH 3T3 CELLS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROVIRIDAE;

EID: 61449191698     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-081     Document Type: Article

References (71)

1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311-1333.
2. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 2002;98:357-361.
3. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neuro-virol. 1998;4:148-158.
4. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995;55:5536-5539.
5. La A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62:3335-3339.
6. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumori-genic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927-2935.
7. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998;12:3675-3685.
8. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf. Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astro-cyte axis. Cancer Cell. 2002;1:269-277.
9. Ding H, Shannon P, Lau N, et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res. 2003;63:1106-1113.
10. Boockvar JA, Kapitonov D, Kapoor G, et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neuro-sci. 2003;24:1116-1130.
11. Moscatello DK, Montgomery RB, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 1996;13:85-96.
12. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem. 1995;270:30562-30566.
13. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem. 1998;273:2817-2822.
14. Lorimer IA, Lavictoire SJ. Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim Biophys Acta. 2001;1538:1-9.
15. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998;273:200-206.
16. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phos-phatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947.
17. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362.
18. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inacti-vation of the pRb pathway predisposes mice to malignant astrocy-toma development that is accelerated by PTEN mutation. Cancer Cell. 2002;1:157-168.
19. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264:29-41.
20. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem. 1998;273:13375-13378.
21. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glio-blastoma multiforme. J Natl Cancer Inst. 2001 ;93:1246-1256.
22. Von Deimling A, Louis DN, von Ammon K, et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg. 1992;77:295-301.
23. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006;106:2218-2223.
24. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol. 1998;57:684-689.
25. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphati-dylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742-2746.
26. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003;22:2812-2822.
27. Klingler-Hoffmann M, Bukczynska P, Tiganis T. Inhibition of phos-phatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer. 2003;105:331-339.
28. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003;9:4340-4346.
29. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024.
30. Wei Q, Clarke L, Scheidenhelm DK, et al. High-grade glioma formation results from postnatal PTEN loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res. 2006;66:7429-7437.
31. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92:3829-3840.
32. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996;93:11400-11406.
33. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci. 1992;12:4565-4574.
34. Trotman LC, Niki M, Dotan ZA, et al. PTEN dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:385-396.
35. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature. 2005;436:725-730.
36. Li L, Liu F, Salmonsen RA, et al. PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci. 2002;20:21-29.
37. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyo-typing of human chromosomes. Science. 1996;273:494-497.
38. Liyanage M, Coleman A, du Manoir S, et al. Multicolour spectral karyo-typing of mouse chromosomes. Nat Genet. 1996;14:312-315.
39. Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 2001;294:2186-2189.
40. Vescovi AL, Reynolds BA, Fraser DD, Weiss S. bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron. 1993;11:951-966.
41. Rong Y, Durden DL, Van Meir EG, Brat DJ. "Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65:529-539.
42. Rietze RL, Valcanis H, Brooker GF, et al. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature. 2001;412:736-739.
43. Mawrin C, Diete S, Treuheit T, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol. 2003;23:641-648.
44. Antonyak MA, Kenyon LC, Godwin AK, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene. 2002;21:5038-5046.
45. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193-204.
46. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157-170.
47. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58:3974-3985.
48. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetra-ploidization as a major route to centrosome amplification in p53-/-cells. EMBO J. 2002;21:483-492.
49. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021.
50. Li B, Yuan M, Kim IA, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astro-cytic origin. Oncogene. 2004;23:4594-4602.
51. Sato S, Fujita N, Tsuruo T. Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem. 2004;279:33759-33767.
52. Byun HJ, Hong IK, Kim E, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem. 2006;281:34833-34847.
53. Li M, Ng SS, Wang J, et al. EFA6A enhances glioma cell invasion through ADP ribosylation factor 6/extracellular signal-regulated kinase signaling. Cancer Res. 2006;66:1583-1590.
54. +/- mice. Science. 1999;285:2122-2125.
55. Kotelevets L, van Hengel J, Bruyneel E, et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol. 2001;155:1129-1136.
56. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
57. 1 cell cycle entry. Proc Natl Acad Sci U S A. 2006;103:111-116.
58. Paling NR, Wheadon H, Bone HK, Welham MJ. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J Biol Chem. 2004;279:48063-48070.
59. Nakamura Y, Yujiri T, Nawata R, Tagami K, Tanizawa Y. MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells. Oncogene. 2005;24:7592-7598.
60. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-913.
61. Mahrhofer H, Burger S, Oppitz U, Flentje M, Djuzenova CS. Radiation induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys. 2006;64:573-580.
62. Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle. 2005;4:927-929.
63. Syljuasen RG, Sorensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 2005;25:3553-3562.
64. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle. 2005;4:131-139.
65. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene. 2006;25:4381-4388.
66. Shtivelman E, Sussman J, Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol. 2002;12:919-924.
67. Schmitt E, Boutros R, Froment C, et al. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J Cell Sci. 2006;119:4269-4275.
68. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22:451-464.
69. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006;25:4831-4839.
70. Kramer A, Mailand N, Lukas C, et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol. 2004;6:884-891.
71. Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell. 2006;21:201-214.